Pharmaceutical Outsourcing Q2 2024 - 17

CLINICAL TRIALS
SECTION TITLE
Beat the Clock: How an
FSP Model Can Optimize a
Follow-the-Sun Approach in
Clinical Development Functions
Gary Barker
Executive Director, Pharmacovigilance,
Functional Service Partnership Solutions
Richard D'Amato
Executive Director, Biostatistics and Programming,
Functional Service Partnership Solutions
Robert King
Executive Director, Functional Service Partnership Solutions
Jennifer Erdmann
Senior Director, Centralized Monitoring
Sarah Frost
Senior Director, Medical Writing,
Functional Service Partnership Solutions
George Weir
Senior Director, Clinical Data Management,
Functional Service Partnership Solutions
Rebecca Sagosz
Regulatory Publishing Project Consultant
All with the PPD Clinical Research Business of Thermo Fisher Scientific
As the race to bring promising new treatments to market intensifies
and the complexity, size, and sophistication of clinical trials grows
exponentially,1
pressure is mounting to deliver on ever-more
challenging timelines. One powerful solution gaining popularity is
the adoption of a follow-the-sun (FTS) model delivered in a flexible
functional service provider (FSP) outsourcing model.
FTS solutions strategically leverage global teams and time zone
differences to maximize productivity and minimize bottlenecks. The
advantages are compelling; however, their implementation requires
flexibility, deep functional capabilities, and operational excellence.
This is where the FSP model shines, offering an approach to outsource
clinical development functions and post-marketing surveillance built
on an adaptable global resource allocation framework.
Because FSP models offer a host of advantages, including flexibility,
a depth and breadth of functional capabilities, global reach, and
the ability to deliver on aggressive timelines, organizations are
increasingly turning to FSP partners to outsource specific functions
of clinical trials (e.g., clinical operations, pharmacovigilance, data
management, biometrics, centralized monitoring, etc.). The result
has been substantial growth. A 2023 survey of biopharma and
biotech leaders revealed an increase in FSP outsourcing over the
past two years with 41% of respondents reporting greater use of
FSP models compared to the full-service outsourcing (FSO) model's
29% growth.2
The survey also found that a mix of hybrid FSP/
FSO models has become more common with FSP or hybrid FSP/
FSO arrangements being used by 87% of drug develeopers. FSP
partnerships are projected to continue growing at a compound
annual growth rate of more than 8.5% from 2024 to 2029.3
Follow-the-Sun Solution: Potential
Benefits for Drug Developers
An FTS approach leverages around-the-clock productivity by using
global teams strategically located across different time zones. In this
model, as the sun rises and sets in different geographies, tasks are
pharmoutsourcing.com | 17 | April/May/June 2024
http://www.pharmoutsourcing.com
Pharmaceutical Outsourcing Q2 2024

Table of Contents for the Digital Edition of Pharmaceutical Outsourcing Q2 2024
